Services from Biosynth

Biosynth is a global life-sciences reagents, custom-synthesis, and contract-manufacturing company headquartered in Staad, Switzerland, with peptide-specific manufacturing operations spanning the United States and the Netherlands — a scale and corporate structure that distinguishes it from the direct-to-researcher retail vendors that make up most of the Peptides.SO supplier directory. Biosynth's peptide division was formed through the 2022 acquisition of Pepscan, a Dutch CDMO founded in 1996 in Lelystad by Rob Meloen that added GMP manufacturing capability in 2018 and built a specialization in neoantigen-based personalized immunotherapy peptides and peptide-based theranostics, combined with the earlier merger of New England Peptide (founded 1998 in Gardner, Massachusetts, by Samuel and Jennifer Massoni, operating a 25,000-square-foot custom peptide and antibody production facility) and Peptides International — together representing more than 40 years of combined U.S. peptide manufacturing history, with additional operations in Louisville, Kentucky.

The division's service scope spans the full peptide development pathway: ready-to-order custom peptide synthesis, lead discovery and optimization, milligram-to-multikilogram production scale-up, and GMP drug-substance manufacturing suitable for clinical trial use. Biosynth's U.S. and Netherlands sites hold ISO 9001:2015 certification, and the Dutch facility is additionally qualified to manufacture GMP peptide drug substance in accordance with EudraLex Volume 4, Part II — a clinical-grade manufacturing qualification not typically held by catalog research-peptide vendors. Specialized offerings include RGD peptide synthesis, personalized peptide libraries, and high-throughput peptide array production for screening applications, positioning this listing as a CDMO service offering for institutional and pharmaceutical research programs rather than a retail research-chemical catalog.